Related Experiment Video
Updated: May 21, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
MICU1 deficiency exacerbates cisplatin-induced acute kidney injury by tubular apoptosis and mitochondrial dysfunction
Boqing Dong1, Huanjing Bi1, Yang Li1
1Department of Renal Transplantation, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Abstract:
Cisplatin-induced acute kidney injury (AKI) is characterized by profound oxidative stress and mitochondrial dysfunction in proximal tubular cells. However, the upstream mechanisms governing this redox imbalance remain incompletely defined. Here, we identify mitochondrial calcium uptake 1 (MICU1) as a critical regulator of tubular redox homeostasis. Using integrated multi-omics approaches, we found that MICU1 is markedly downregulated in injured proximal tubular subpopulations across various kidney diseases. Mechanistically, MICU1 deficiency disrupts mitochondrial calcium homeostasis, resulting in calcium overload and excessive mitochondrial reactive oxygen species (mtROS) generation. These changes trigger intrinsic apoptotic pathways, whereas MICU1 restoration alleviates such damage. Furthermore, we demonstrate that the ARNT/HIF-1α axis transcriptionally regulates MICU1. Under cisplatin stress, this axis is suppressed, thereby promoting mitochondrial dysfunction. Crucially, we found that MICU1-mediated mtROS control contributes to the preservation of epidermal growth factor receptor (EGFR) signaling, whereas excessive mtROS accumulation is associated with EGFR signaling impairment. Importantly, pharmacological targeting of mitochondrial calcium uptake using the small-molecule modulator MCU-i4 attenuates calcium overload, suppresses mtROS accumulation, and mitigates renal injury in vitro and in vivo. Collectively, our findings support a transcriptional-mitochondrial axis linking calcium dysregulation to oxidative stress and identify MICU1 as a potential therapeutic target for redox-driven kidney injury.
Insights
Mitochondrial calcium uptake 1 (MICU1) deficiency worsens cisplatin-induced kidney injury by increasing oxidative stress. Restoring MICU1 or targeting mitochondrial calcium uptake may protect against kidney damage.
Area of Science:
- Nephrology
- Mitochondrial Biology
- Cellular Redox Homeostasis
Background:
- Cisplatin causes acute kidney injury (AKI) via oxidative stress and mitochondrial dysfunction.
- Upstream regulators of this redox imbalance in kidney tubular cells are not fully understood.
Purpose of the Study:
- Identify key regulators of redox homeostasis in kidney proximal tubular cells.
- Elucidate the role of mitochondrial calcium uptake 1 (MICU1) in AKI pathogenesis.
- Investigate therapeutic strategies targeting mitochondrial calcium.
Main Methods:
- Integrated multi-omics analysis of kidney tissues.
- In vitro and in vivo models of cisplatin-induced AKI.
- Assessment of mitochondrial calcium, reactive oxygen species (ROS), apoptosis, and signaling pathways.
- Pharmacological intervention with MCU-i4.
Main Results:
- MICU1 is downregulated in injured proximal tubular cells across kidney diseases.
- MICU1 deficiency causes mitochondrial calcium overload, excessive mitochondrial ROS (mtROS), and apoptosis.
- The ARNT/HIF-1α axis suppresses MICU1 under cisplatin stress, impairing mitochondrial function.
- MICU1-mediated mtROS control preserves epidermal growth factor receptor (EGFR) signaling.
- Pharmacological inhibition of mitochondrial calcium uptake (MCU-i4) mitigates renal injury.
Conclusions:
- MICU1 is a critical regulator of tubular redox homeostasis and a potential therapeutic target for AKI.
- A transcriptional-mitochondrial axis involving calcium dysregulation, oxidative stress, and MICU1 contributes to kidney injury.
- Targeting mitochondrial calcium uptake offers a promising strategy to treat redox-driven kidney diseases.

